Covid 19 Treatment Articles & Analysis
49 news found
” “For heart failure patients, the initial evaluation of volume status informs the initial and subsequent treatment plans and sets the course for post-acute care and subsequent risk of readmission,” said Jean Oertel, Daxor’s Sr. ...
Data were presented at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-based treatments in heart failure. The conference was held March 20-22, 2023 in Boston, Mass. ...
Study results showed little to no correlation between physician assessment of congestion on admission compared to BVA results, and those that received BVA-guided treatment had a strong trend toward lower total hospital length of stay (2.7 fewer days, P<0.09). ...
Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. ...
Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. ...
Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. ...
Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. ...
Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. ...
Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. ...
“Daxor is honored to be featured in this exciting MedAxiom Academy webinar. BVA guided treatment in heart failure has shown to reduce heart failure 30-day readmissions by 56%, 30-day mortality by 82%, 1-year mortality by 86% and when done on admission, lowers hospital length of stay by 55%. Our diagnostic provides 98% accurate, objective, and actionable data to ...
Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. ...
“The AHA Scientific Sessions is a leading event connecting over 15,000 experts from over one hundred countries focused on cardiovascular research and clinical practice. BVA guided treatment in heart failure has shown to reduce heart failure 30-day readmissions by 56%, 30-day mortality by 82%, 1-year mortality by 86% and when done on admission, lowers hospital length of stay ...
(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
He went on to say that “The Daxor methodology is simple, can be done at the bedside and more practical clinically to help guide individualized treatment.” The panel unanimously agreed that pressure and volume do not give the same clinical information. ...
Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. ...
Blood volume expansion was present in over 50% of the overall cohort with normal blood volume only present in 27% at the time of hospital discharge and a risk in particular for right ventricular dysfunction was highlighted as being particularly challenging. Despite treatment to resolve volume abnormalities, the study author noted “Persistent intravascular volume expansion ...
” “Understanding the impact of treatment decisions on outcomes for the over-65 population is of relevance to U.S. healthcare, as decisions made by the Centers for Medicare & Medicaid Services (CMS) regarding reimbursement, outcome-based incentives and penalties applied to health providers, and indication guidelines have enormous impact on how healthcare is ...
“This important study shows that BVA has the ability to help clinicians treat patients more effectively so that they get out of the hospital faster and have better results in terms of mortality and readmission when compared to those who did not receive BVA-guided care. Annual costs for HF treatment are estimated at $30.7 billion and expected to grow to nearly $70 billion ...
“The HFSA’s Annual Scientific Meeting is the premier event that gathers the best scientific minds focused on the latest heart failure science, research and patient management,” said Michael Feldschuh, CEO and President of Daxor Corporation. “BVA guided treatment in heart failure has shown to reduce heart failure 30-day readmissions by 56%, 30-day mortality ...
Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. ...